Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease

Nicotine and Tobacco Research

Volumn 16, Issue 8, 2014, Pages

  O'Malley, Stephanie S ^a,b   Wu, Ran ^a   Mayne, Susan T ^b,c   Jatlow, Peter I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; ASPARTIC ACID; BILIRUBIN; NALTREXONE; NICOTINE PATCH; PLACEBO; NICOTINE; NICOTINE GUM;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; RISK REDUCTION; SMOKING CESSATION; BLOOD; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; DRUG THERAPY; INTRADERMAL DRUG ADMINISTRATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIOXIDANTS; BILIRUBIN; CARDIOVASCULAR DISEASES; COUNSELING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NALTREXONE; NICOTINE; RISK FACTORS; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84904337418     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntu067     Document Type: Article

References (29)

1. Benowitz, N. L. (2007). Cigarette smoking and the personalization of irinotecan therapy. Journal of Clinical Oncology, 25, 2646-2647. doi:10.1200/JCO.2007.10.7359.
2. Cheriyath, P., Gorrepati, V. S., Peters, I., Nookala, V., Murphy, M. E., Srouji, N., & Fischman, D. (2010). High total bilirubin as a protective factor for diabetes mellitus: An analysis of NHANES data from 1999-2006. Journal of Clinical Medicine Research, 2, 201-206. doi:10.4021/jocmr425w.
3. Fischman, D., Valluri, A., Gorrepati, V. S., Murphy, M. E., Peters, I., & Cheriyath, P. (2010). Bilirubin as a protective factor for rheumatoid arthritis: An NHANES study of 2003-2006 data. Journal of Clinical Medicine Research, 2, 256-260. doi:10.4021/jocmr444w.
4. Hollands, G. J., Hankins, M., & Marteau, T. M. (2010). Visual feedback of individuals' medical imaging results for changing health behaviour. Cochrane Database of Systematic Reviews, (1), CD007434.
5. Hopkins, P. N., Wu, L. L., Hunt, S. C., James, B. C., Vincent, G. M., & Williams, R. R. (1996). Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arteriosclerosis Thrombosis Vascular Biology, 16, 250-255. doi:10.1161/01.ATV.16.2.250.
6. Horsfall, L. J., Rait, G., Walters, K., Swallow, D. M., Pereira, S. P., Nazareth, I., & Petersen, I. (2011). Serum bilirubin and risk of respiratory disease and death. Journal of the American Medical Association, 305, 691-697. doi:10.1001/jama.2011.124.
7. Jo, J., Kimm, H., Yun, J. E., Lee, K. J., & Jee, S. H. (2012). Cigarette smoking and serum bilirubin subtypes in healthy Korean men: The Korea Medical Institute study. Journal of Preventive Medicine and Public Health, 45, 105-112. doi:10.3961/jpmph.2012.45.2.105.
8. Kristenson, H. (1987). Methods of intervention to modify drinking patterns in heavy drinkers. Recent Developments in Alcoholism, 5, 403-423. doi:10.1007/978-1-4899-1684-6_17.
9. Madhavan, M., Wattigney, W. A., Srinivasan, S. R., & Berenson, G. S. (1997). Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis, 131, 107-113. doi:10.1016/S0021-9150(97)06088-7.
10. Merz, M., Seiberling, M., & Thomann, P. (1998). Laboratory values and vital signs in male smokers and nonsmokers in phase I trials: A retrospective comparison. Journal of Clinical Pharmacology, 38, 1144-1150.
11. Morita, K., Tsukamato, T., Naya, M., Noryasu, K., Inubushi, M., Shiga, T., Tamaki, N. (2006). Smoking cessation normalizes coronary endothelial vasomotor response assessed by 15O-water and PET in healthy young smokers. Journal of Nuclear Medicine, 47, 1914-1920.
12. Nilssen, O. (1991). The Tromsö Study: Identification of and a controlled intervention on a population of early stage risk drinkers. Preventative Medicine, 20, 518-528. doi:10.1016/0091-7435(91)90049-A.
13. Novotny, L., & Vitek, L. (2003). Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies. Experimental Biology and Medicine, 228, 568-571.
14. O'Malley, S. S., Cooney, J. L., Krishnan-Sarin, S., Dubin, J. A., McKee, S. A., Cooney, N. L., Jatlow, P. (2006). A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of Internal Medicine, 166, 667-674. doi:10.1001/archinte.166.6.667.
15. Parkes, G. (2008). Effect on smoking quit rate of telling patients their lung age: The Step2quit randomized controlled trial. British Medical Journal, 336, 598-600.
16. Rigotti, N. A. (1996). Cigarette smoking and coronary heart disease: Risks and management. Cardiology Clinics, 14, 51-68. doi:10.1016/S0733-8651(05)70260-5.
17. Rizzo, A. M., Berselli, P., Zava, S., Montorfano, G., Negroni, M., Corsetto, P., & Berra, B. (2010). Endogenous antioxidants and radical scavengers. Advances in Experimental Medicine and Biology, 698, 52-67. doi:10.1007/978-1-4419-7347-4_5.
18. Schwertner, H. A. (1998). Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis, 136, 383-387.
19. St. Helen, G., Goniewicz, M. L., Dempsey, D., Wilson, M., Jacob, P., III, & Benowitz, N. L (2012) Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chemical Research and Toxicology, 25:952-964.
20. Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., & Ames, B. N. (1987). Bilirubin is an antioxidant of possible physiological importance. Science, 235, 1043-1046. doi:10.1126/science.3029864.
21. Temme, E. H., Zhang, J., Schouten, E. G., & Kesteloot, H. (2001). Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes & Control, 12, 887-894.
22. U.S. Department of Health and Human Services. (2014). The health consequences of smoking-50 years of progress: A report of the surgeon general. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
23. van der Bol, J. M., Mathijssen, R. H., Loos, W. J., Friberg, L. E., van Schaik, R. H., de Jonge, M. J., de Jong, F. A. (2007). Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia. Journal of Clinical Oncology, 25, 2719-2726. doi:10.1200/jco.2006.09.6115.
24. Van Hoydonck, P. G., Temme, E. H., & Schouten, E. G. (2001). Serum bilirubin concentration in a Belgian population: The association with smoking status and type of cigarettes. International Journal of Epidemiology, 30, 1465-1472. doi:10.1093/ije/30.6.1465.
25. Watchko, J. F., & Tiribelli, C. (2013). Bilirubin-induced neurologic damage--mechanisms and management approaches. The New England Journal of Medicine, 369, 2021-2030.
26. White, G. L., Jr., Nelson, J. A., Pedersen, D. M., & Ash, K. O. (1981). Fasting and gender (and altitude?) influence reference intervals for serum bilirubin in healthy adults. Clinical Chemistry, 27, 1140-1142.
27. Zevin, S., & Benowitz, N. L. (1999). Drug interactions with tobacco smoking. An update. Clinical Pharmacokinetics, 36, 425-438. doi:10.2165/00003088-199936060-00004
28. Zhang, F., Wen, C. P., Liang, D., Skinner, H., Gu, J., Chow, W.-H.,..Wu, X. (2013). Metabolomic profiling identifies bilirubin as a novel serum marker of lung cancer. Cancer Research, 73(Suppl. 1), 10.
29. Zucker, S. D., Horn, P. S., & Sherman, K. E. (2004). Serum bilirubin levels in the U.S. population: Gender effect and inverse correlation with colorectal cancer. Hepatology, 40, 827-835. doi:10.1002/hep.20407